Skip to main content
ConductScienceScienceDex

Donald W. Kufe

NIH Rank #1910
Unclaimed recordClaim profile
  • R01 Holder
  • Top 10% Funded
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1898917Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine

NIH Funding · FY2024

Linked Award Amount
$3.6M
Full award amounts, FY2024
Award Records
4
Records listing this PI
Award-Linked Rank
#1,910
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Donald W. Kufe. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Donald W. Kufe as a PI. Multi-PI records show the full award amount for context.

  • 5UM1CA186709-08UM1
    Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
    Dana-Farber Cancer Institute
    $2M
    award amount
  • 1R01CA282437-01A1R01
    Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer
    NYU Grossman School of Medicine
    $735K
    award amount
  • 2R01CA097098-20A1R01
    Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
    Dana-Farber Cancer Institute
    $466.6K
    award amount
  • 1R21CA289134-01R21
    MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
    Dana-Farber Cancer Institute
    $450.4K
    award amount

Award organizations

Organizations that administered FY2024 awards listing Donald W. Kufe as a PI.

Dana-Farber Cancer Institute
MA
$2.9M
3 grants
NYU Grossman School of Medicine
NY
$735K
1 grant

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Dana-Farber Cancer Institute
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #1910
  6. 2024
    Entered Top 25% Nationally
    Ranked #1910
  7. 2024
    Entered Top 10% Nationally
    Ranked #1910
  8. 2025
    $5M Cumulative Funding
  9. 2025
    Multi-Institutional Research
    Awards at 2 institutions
  10. 2025
    R01 Grant Holder
  11. 2026
    $10M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Donald W. Kufe.

Geoffrey I. Shapiro
Dana-Farber Cancer Institute
4
shared awards
Keith T Flaherty
Dana-Farber Cancer Institute
4
shared awards
Kwok Kin Wong
NYU Grossman School of Medicine
3
shared awards

Explore further

Find collaborators for Donald W. Kufe

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →